KAHF Biotech is in preliminary stage of development. The mission of company is to open a new avenue for treatment and prevention of cancer metastasis.
Muhammad Sadeqi Nezhad is a cancer researcher at University of Rochester Medical Center, New York, USA. Currently, he is working with a great team on development of cancer therapeutics for pancreatic cancer patients at Wilmot Cancer Institute. One of his research desires is to develop novel therapeutic approaches for cancer patients with metastasis.
Besides the cancer research, He is working at Office of Technology Transfer at University of Rochester (URVenture). He as an entrepreneur, is seeking to find pains in his research area to design and develop a novel therapeutic and preventive technologies with great unmet market need.
The company’s focus is on Cancer Plasticity and Metastasis.